GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic.

1 report, 1 independent Updated Aug 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

CureVac GSK Pfizer

How it developed

Newest first. Tap a step to see who reported it.

Jun 7GSK and CureVac reached a settlement regarding patent disputes, with Pfizer covering part of the payouts.Sub-event
Aug 11GSK/CureVac patent dispute adds new dimension to the existing mRNA vaccine technology focus.1 source
- Investing.com

Keep exploring

Part of

CureVac announced updates from Tübingen and Boston, leading to EMA granting CTA clearance for CVHNLC based on mRNA vaccine patents. All 1 developments

The entities involved

CureVac
biopharmaceutical company in Germany

Nothing else this week.
GSK
British multinational pharmaceutical and biotechnology company
- Uncertainty over a dispute involving GSK and AnaptysBio weighed on market sentiment.Sat 23:22
- FDA approved a GSK drug and authorized a Roche blood test for eligibility, amidst estimates of 1.7M chronic HBV patients in the US.Fri 12:54
Pfizer
American multinational pharmaceutical and biotechnology corporation
- MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.Sat 18:12
- PepsiCo, Meta, Toyota, Google, and Pfizer contributed founding council members to the Peerworks initiative led by Zero100.Fri 10:24

Coverage

Newest first; wire copies grouped

Aug 11Investing.comGSK climbs after winning FDA priority review for oral gonorrhoea antibiotic Investing.com -- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priori